Leukaemia Foundation receives HONcode certification
Friday, 07 December 2018
The Leukaemia Foundation has been granted prestigious HONcode certification for its high standard of reliable, ethical and trustworthy health and medical content featured throughout its digital communications platforms.
The HONcode is an international standard for health and medical websites issued by the Health on the Net Foundation,
Researchers at the Peter MacCallum Cancer Centre in Melbourne believe a new combination therapy for mantle cell lymphoma could lead to a cure in almost 100 per cent of cases.
Wednesday, 05 December 2018
A story in the Sydney Morning Herald recently reported Australian researchers were closing in on a cure for the disease which was considered a “death sentence” as little as three years ago.
Peter MacCallum Cancer Centre Professor Sarah-Jane Dawson said dozens of people living with mantle
New PBS listing vital to Australians living with Acute Myeloid Leukaemia
Friday, 30 November 2018
Leukaemia Foundation CEO Mr Bill Petch has today supported the Health Minister Mr Greg Hunt’s Pharmaceuticals Benefits Scheme (PBS) listing announcement of midostaurin (Rydapt®), a targeted therapy that is considered to be an important advancement in the treatment of Acute Myeloid Leukaemia (AML) in 25 years.
Leukaemia Foundation and HSANZ Jointly Funds Three PhD Investigators
Thursday, 8 November 2018
The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) are proud to announce the co-funding of three Australian Clinical and Science PhD investigators, whose work will focus on understanding blood cancer biology and the development of new diagnostics and precision medicines.
Position Statement: Glyphosate
Monday, 22 October 2018
In August 2018, a landmark US court case against Monsanto, the manufacturer of weed killer Roundup, ruled a chemical used in the product (glyphosate) was a substantial factor in causing a school ground keeper’s terminal cancer and that the company had failed to warn of the
Leukaemia Foundation supports WEHI’s new laboratory model to test anti-cancer drugs
Tuesday, 16 October 2018
A new model which mimics the complexity of human cancers to allow for more accurate testing of anti-cancer drugs has been developed by leading Australian researchers at the Walter and Eliza Hall Institute (WEHI) in Melbourne.
Led by PhD students Ms Margs Brennan and Dr Gemma Kelly
Leukaemia Foundation supports Health Minister’s call to introduce ground breaking CAR-T Cell therapies into Australian Public Hospitals
Tuesday, 16 October 2018
The Leukaemia Foundation has come out in support of today’s call by Federal Health Minister Greg Hunt to fast track the revolutionary CAR T-Cell therapy into Australian hospitals.
CAR-T cell therapy involves harvesting a patient’s T-cells, a type of immune cell, and genetically engineering them to attack
Congratulations to Nobel Prize immunotherapy pioneers
Thursday, 04 October 2018
The Leukaemia Foundation congratulates the 2018 Nobel Prize in Medicine winners, James Allison of the US and Tasuku Honjo of Japan, for their research and discovery into how the body’s natural defences can fight cancer such as lymphoma.
“As Australia’s leading blood cancer organisation, we acknowledge the
Follicular lymphoma and multiple myeloma treatment now available to Australians through $48m PBS listing
Monday, 01 October 2018
The Leukaemia Foundation welcomes the Federal Government’s announcement confirming new medicine for both follicular lymphoma and multiple myeloma will be added to Pharmaceutical Benefits Scheme (PBS) from 1 October 2018.
Leukaemia Foundation CEO Bill Petch said the PBS listing of Gazyva (obinutuzumab) would benefit around 700 people
Lymphoma and myeloma treatments to be subsidised through $48m PBS listing
The Leukaemia Foundation has applauded the Federal Government’s recent announcement of funding $48 million towards more affordable drugs for Australians living with blood cancer.
Leukaemia Foundation CEO Bill Petch said the Pharmaceutical Benefits Scheme (PBS) listing of Gazyva (obinutuzumab) this October